On August 13, 2021 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, reported it will present data on Rhenium-186 NanoLiposome (186RNL) from its Phase 1 ReSPECT clinical trial in recurrent glioblastoma (GBM) at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting (AANS) being held virtually August 21-25, 2021 (Press release, Cytori Therapeutics, AUG 13, 2021, View Source [SID1234586543]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the ePoster presentation are as follows:

Title A two-part, Phase 1 study of Rhenium-186 NanoLiposome (186RNL) delivered by convection enhanced delivery for recurrent, refractory, or progressive ependymoma and high-grade glioma (HGG) and newly diagnosed diffuse intrinsic pontine glioma (DIPG)
Date Poster presentations will become available to conference participants on-demand beginning Saturday, August 21, 2021
Presenter Michael G. DeCuypere, MD, PhD, FAANS, Northwestern University Feinberg School of Medicine, and study investigator
A copy of the poster will be made available under the Presentations tab of the Investors section of the Company’s website at the time of the presentation at www.plustherapeutics.com.